Researchers call on FDA to get tough on accelerated approval labeling

More than 10% of drugs granted accelerated approval by the US Food and Drug Administration (FDA) have not complied with the agency’s 2019 labeling guidance, according to a new study. The study authors wrote that the lack of labeling transparency can affect prescribing habits and call on FDA to ensure regulatory compliance through meetings with manufacturers, warning letters or by levying fines.